TransMedics Group, Inc. (NASDAQ:TMDX) Receives $124.18 Average PT from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned a consensus recommendation of “Hold” from the thirteen research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $124.1818.

A number of research firms recently commented on TMDX. Stifel Nicolaus boosted their target price on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. TD Cowen restated a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a report on Tuesday, September 8th. Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a research note on Friday. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Finally, Piper Sandler reiterated an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th.

Insiders Place Their Bets

In related news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently made changes to their positions in TMDX. Candriam S.C.A. raised its position in TransMedics Group by 45.4% in the 1st quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock worth $15,783,000 after purchasing an additional 49,580 shares during the period. Emerald Investment Advisers LLC purchased a new position in shares of TransMedics Group during the second quarter valued at approximately $2,023,000. Deutsche Bank AG purchased a new position in shares of TransMedics Group during the second quarter valued at approximately $14,415,000. Regency Capital Management Inc. DE bought a new position in shares of TransMedics Group during the first quarter valued at approximately $2,172,000. Finally, Headlands Technologies LLC purchased a new stake in shares of TransMedics Group in the second quarter worth approximately $1,634,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $82.18 on Thursday. The company has a market cap of $2.84 billion, a P/E ratio of 21.13 and a beta of 1.90. TransMedics Group has a 52-week low of $60.10 and a 52-week high of $156.00. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The firm’s fifty day moving average is $82.00 and its two-hundred day moving average is $90.58.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same period last year, the company earned $0.92 EPS. As a group, analysts anticipate that TransMedics Group will post 1.46 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.